• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Lilly Slaps $8,000-Per-Treatment-Cycle Price Tag On Lung Cancer Drug


December 21, 2015.

FDA News reports that Eli Lilly has put a premium price tag on its new lung cancer drug Portrazza: $8,000 per treatment cycle.

FDA approved the drug, which is indicated for patients with squamous non-small cell lung cancer, in late November.

Lilly spokeswoman Carla Cox said the average patient will require six courses of treatment, which at $8,000 for each cycle works out to $48,000. But, FDA News adds, "she stressed that very few patients would ever pay this price, due to insurance coverage, medical assistance programs and price negotiations between industry and insurers".


Recent Videos
Related Content